USD 0.34
(-6.48%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 12.42 Million USD | 3.32% |
2022 | 12.02 Million USD | -55.67% |
2021 | 27.12 Million USD | -15.35% |
2020 | 32.04 Million USD | 66.14% |
2019 | 19.28 Million USD | 16.34% |
2018 | 16.57 Million USD | 62.87% |
2017 | 10.17 Million USD | 218.17% |
2016 | 3.19 Million USD | 624.71% |
2015 | 441.42 Thousand USD | -12.44% |
2014 | 504.11 Thousand USD | 205.52% |
2013 | 165 Thousand USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 11.4 Million USD | -8.24% |
2024 Q2 | 11.81 Million USD | 3.61% |
2023 FY | 12.42 Million USD | 3.32% |
2023 Q1 | 9.76 Million USD | -18.82% |
2023 Q4 | 12.42 Million USD | 15.18% |
2023 Q2 | 9.46 Million USD | -3.09% |
2023 Q3 | 10.78 Million USD | 14.01% |
2022 Q3 | 23.12 Million USD | 1.77% |
2022 FY | 12.02 Million USD | -55.67% |
2022 Q1 | 22.16 Million USD | -18.29% |
2022 Q2 | 22.72 Million USD | 2.53% |
2022 Q4 | 12.02 Million USD | -48.0% |
2021 Q1 | 28.62 Million USD | -10.66% |
2021 FY | 27.12 Million USD | -15.35% |
2021 Q2 | 27.79 Million USD | -2.9% |
2021 Q3 | 27.11 Million USD | -2.46% |
2021 Q4 | 27.12 Million USD | 0.04% |
2020 Q1 | 21.53 Million USD | 11.64% |
2020 FY | 32.04 Million USD | 66.14% |
2020 Q2 | 27.54 Million USD | 27.92% |
2020 Q3 | 30.83 Million USD | 11.94% |
2020 Q4 | 32.04 Million USD | 3.93% |
2019 Q4 | 19.28 Million USD | 2.92% |
2019 FY | 19.28 Million USD | 16.34% |
2019 Q1 | 15.93 Million USD | 6.05% |
2019 Q2 | 17.82 Million USD | 11.92% |
2019 Q3 | 18.73 Million USD | 5.1% |
2018 Q1 | 13.7 Million USD | 34.63% |
2018 Q4 | 15.02 Million USD | 25.29% |
2018 Q3 | 11.99 Million USD | 2.29% |
2018 Q2 | 11.72 Million USD | -14.46% |
2018 FY | 16.57 Million USD | 62.87% |
2017 FY | 10.17 Million USD | 218.17% |
2017 Q4 | 10.17 Million USD | 2.3% |
2017 Q3 | 9.95 Million USD | 49.07% |
2017 Q2 | 6.67 Million USD | 88.07% |
2017 Q1 | 3.54 Million USD | 10.94% |
2016 Q4 | 3.19 Million USD | 41.26% |
2016 FY | 3.19 Million USD | 624.71% |
2016 Q3 | 2.26 Million USD | 182.3% |
2016 Q2 | 802.19 Thousand USD | 15.82% |
2016 Q1 | 692.59 Thousand USD | 56.9% |
2015 Q1 | 528.05 Thousand USD | 4.75% |
2015 FY | 441.42 Thousand USD | -12.44% |
2015 Q4 | 441.42 Thousand USD | -25.2% |
2015 Q3 | 590.12 Thousand USD | 10.07% |
2015 Q2 | 536.11 Thousand USD | 1.53% |
2014 FY | 504.11 Thousand USD | 205.52% |
2014 Q4 | 504.11 Thousand USD | 205.52% |
2014 Q3 | 165 Thousand USD | 0.0% |
2014 Q2 | 165 Thousand USD | 0.0% |
2014 Q1 | 165 Thousand USD | 0.0% |
2013 Q3 | 150 Thousand USD | 0.0% |
2013 FY | 165 Thousand USD | 0.0% |
2013 Q4 | 165 Thousand USD | 10.0% |
2013 Q1 | 125 Thousand USD | -18.69% |
2013 Q2 | - USD | -100.0% |
2012 Q3 | 124.73 Thousand USD | 0.0% |
2012 Q4 | 153.73 Thousand USD | 23.25% |
2012 FY | - USD | 0.0% |
2012 Q1 | 14.82 Thousand USD | 20.0% |
2012 Q2 | - USD | -100.0% |
2011 Q4 | 12.35 Thousand USD | 147.04% |
2011 Q1 | 5000.00 USD | -68.5% |
2011 Q2 | - USD | -100.0% |
2011 Q3 | 5000.00 USD | 0.0% |
2011 FY | - USD | 0.0% |
2010 Q3 | 15.87 Thousand USD | 0.0% |
2010 Q2 | - USD | -100.0% |
2010 Q1 | 15.87 Thousand USD | 0.0% |
2010 Q4 | 15.87 Thousand USD | 0.0% |
2010 FY | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q4 | 15.87 Thousand USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 674.28 Million USD | 98.157% |
Embecta Corp. | 1.63 Billion USD | 99.242% |
ANI Pharmaceuticals, Inc. | 315.32 Million USD | 96.06% |
Dynavax Technologies Corporation | 256.91 Million USD | 95.164% |
Esperion Therapeutics, Inc. | 540.94 Million USD | 97.703% |
Pacira BioSciences, Inc. | 586.04 Million USD | 97.88% |
PainReform Ltd. | 86 Thousand USD | -14346.456% |
Aquestive Therapeutics, Inc. | 98.82 Million USD | 87.428% |
Sunshine Biopharma, Inc. | 657.7 Thousand USD | -1788.985% |
SCYNEXIS, Inc. | 15.08 Million USD | 17.613% |
China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -369.279% |
Journey Medical Corporation | 17.73 Million USD | 29.927% |
Sunshine Biopharma, Inc. | 657.7 Thousand USD | -1788.985% |
Safety Shot Inc | 1.54 Million USD | -702.076% |
Alpha Teknova, Inc. | 30.45 Million USD | 59.21% |
Intra-Cellular Therapies, Inc. | 16.93 Million USD | 26.65% |
Bright Green Corporation | 1.85 Million USD | -570.918% |
Procaps Group, S.A. | 285.93 Million USD | 95.655% |
Theratechnologies Inc. | 58.96 Million USD | 78.931% |
Harrow Health, Inc. | 190.5 Million USD | 93.478% |
Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -1943.413% |
Biofrontera Inc. | 5.39 Million USD | -130.116% |
DURECT Corporation | 20.74 Million USD | 40.114% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 70.082% |
Cronos Group Inc. | 2.53 Million USD | -389.144% |
OptiNose, Inc. | 131.74 Million USD | 90.57% |
Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 98.264% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | 65.796% |
RedHill Biopharma Ltd. | 1.17 Million USD | -959.155% |
Organogenesis Holdings Inc. | 119.35 Million USD | 89.59% |
Guardion Health Sciences, Inc. | - USD | -Infinity% |
Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 32.583% |
Radius Health, Inc. | 365.31 Million USD | 96.599% |
Universe Pharmaceuticals INC | 5.48 Million USD | -126.613% |
ProPhase Labs, Inc. | 21.38 Million USD | 41.89% |
Phibro Animal Health Corporation | 525.45 Million USD | 97.636% |
Procaps Group S.A. | 285.93 Million USD | 95.655% |
Alvotech | 1.07 Billion USD | 98.845% |
TherapeuticsMD, Inc. | 8 Million USD | -55.202% |
Viatris Inc. | 18.12 Billion USD | 99.931% |
Rockwell Medical, Inc. | 13.43 Million USD | 7.553% |
Aytu BioPharma, Inc. | 15.12 Million USD | 17.88% |
SIGA Technologies, Inc. | 1.46 Million USD | -748.625% |
Tilray Brands, Inc. | 387.31 Million USD | 96.792% |
Lifecore Biomedical, Inc. | 130.36 Million USD | 90.47% |
Shineco, Inc. | 29.65 Million USD | 58.107% |
PetIQ, Inc. | 468.3 Million USD | 97.347% |
Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -20673.408% |
Incannex Healthcare Limited | 373 Thousand USD | -3230.818% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | 97.1% |
Alimera Sciences, Inc. | 67.39 Million USD | 81.567% |
Silver Spike Investment Corp. | - USD | -Infinity% |
Assertio Holdings, Inc. | 40.91 Million USD | 69.632% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -1042.229% |
Petros Pharmaceuticals, Inc. | 8.27 Million USD | -50.11% |
Clever Leaves Holdings Inc. | 2.08 Million USD | -495.302% |
Cyclo Therapeutics, Inc. | 1.03 Million USD | -1102.572% |
Avadel Pharmaceuticals plc | 35.38 Million USD | 64.888% |
Hempacco Co., Inc. | 13.72 Million USD | 9.476% |
Talphera, Inc. | - USD | -Infinity% |
Alvotech | 1.07 Billion USD | 98.845% |
Eagle Pharmaceuticals, Inc. | 62.46 Million USD | 80.111% |
Lantheus Holdings, Inc. | 616.94 Million USD | 97.986% |
Currenc Group, Inc. | 31.94 Million USD | 61.107% |
Kamada Ltd. | 8.74 Million USD | -42.004% |
Indivior PLC | 281.6 Million USD | 95.588% |
Evoke Pharma, Inc. | 5 Million USD | -148.479% |
Flora Growth Corp. | 3.67 Million USD | -238.343% |
Cyclo Therapeutics, Inc. | 1.03 Million USD | -1102.572% |
Evolus, Inc. | 126.54 Million USD | 90.182% |
HUTCHMED (China) Limited | 86.13 Million USD | 85.576% |
Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 98.008% |
Akanda Corp. | 3.99 Million USD | -210.693% |